IL17A and systemic sclerosis: To elucidate the role of the ERK1/2, PD 98059 (ERK1/2 inhibitor) and SB 203580 (P38 inhibitor) were used to treat SSc patient-derived DVSMCs in the presence of IL-17A or serum from patients with SSc.